FOURIER was the big news out of ACC, but other PCSK9 inhibitor trials mattered as well, including its EBBINGHAUS substudy and the SPIRE and ORION-1 trials. Dr. Steven Nissen outlines the takeaways.
Participating Cleveland Clinic investigator says evolocumab’s sustained LDL reductions over 11 months and halving of cardiovascular event rates suggest “we are on the right track” with PCSK9 inhibitors.
These monoclonal antibodies have sped from bench to bedside with consistent evidence of unprecedented LDL-C lowering and no safety concerns to date. Approvals are likely in 2015 while long-term outcome trials continue.
Certain topics presented at ACC 2014 are likely to have greater impact on patient care than others. Steven Nissen, MD, chairman of Cardiovascular Medicine at Cleveland Clinic, shares his top five choices.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
PSCK9 inhibitors are demonstrating safe, significant LDL-lowering ability in patients for whom therapy with statins or ezetimibe is not sufficient or not tolerated.